Linganisha mbinu
Pitia mbinu ulizochagua bega kwa bega; safu zinazotofautiana zinaangaziwa.
| Uchambuzi Linganishi wa Utekelezaji wa Kilele cha ChIP-seq× | Utafiti wa Chama cha Epigenome-kote (EWAS)× | |
|---|---|---|
| Nyanja | Bioinformatiki | Bioinformatiki |
| Familia | Process / pipeline | Process / pipeline |
| Mwaka wa asili≠ | 2011-2012 | 2008–2011 (term and framework established c. 2011) |
| Mwanzilishi≠ | Rory Stark and Gordon Brown (DiffBind framework); broader ENCODE community | Rakyan, Down, Balding & Beck (conceptual framework); Illumina arrays enabled large-scale application |
| Aina≠ | Comparative genomic signal analysis pipeline | Population-scale epigenomic association study |
| Chanzo asilia≠ | Ross-Innes, C. S., Stark, R., Teschendorff, A. E., Holmes, K. A., Ali, H. R., Dunning, M. J., Brown, G. D., Gojis, O., Ellis, I. O., Green, A. R., Ali, S., Chin, S. F., Palmieri, C., Caldas, C., & Carroll, J. S. (2012). Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature, 481(7381), 389-393. link ↗ | Rakyan, V. K., Down, T. A., Balding, D. J., & Beck, S. (2011). Epigenome-wide association studies for common human diseases. Nature Reviews Genetics, 12(8), 529–541. DOI ↗ |
| Majina mbadala | differential ChIP-seq, ChIP-seq differential binding analysis, comparative peak calling, differential chromatin occupancy analysis | EWAS, methylome-wide association study, epigenetic association study, DNA methylation association study |
| Zinazohusiana≠ | 6 | 5 |
| Muhtasari≠ | Differential ChIP-seq peak calling identifies genomic loci where a protein of interest — typically a transcription factor or histone mark — shows significantly altered binding or occupancy between two or more biological conditions. By combining standard ChIP-seq peak detection with count-based statistical testing, the method reveals condition-specific regulatory elements, providing a genome-wide map of dynamic chromatin interactions underlying cellular state changes. | An epigenome-wide association study (EWAS) is a hypothesis-free, genome-scale method that systematically tests whether epigenetic marks — predominantly CpG-site DNA methylation — differ between individuals with and without a trait, disease, or exposure. By scanning hundreds of thousands of genomic positions simultaneously, EWAS identifies loci where the epigenome is reproducibly associated with a phenotype, offering a layer of biological regulation that classical GWAS does not capture. |
| ScholarGateSeti ya data ↗ |
|
|